SAN DIEGO--(BUSINESS WIRE)--DERMALA, Inc., a consumer dermatology company developing novel, personalized, microbiome-based solutions for acne and other skin conditions, announced today that it has closed a $6.73 million Series A financing. The company developed an integrated platform that combines patent-pending microbiome-based topical and oral products containing unique prebiotic, probiotic, and postbiotic ingredients, including the SE Microbiome Complex®, with a proprietary data analytics app that enables personalization and continuous optimization of product formulations based on individual outcomes.
“The consumer dermatology category is ripe for science-based solutions to treat common skin conditions,” said Lada Rasochova, Ph.D., MBA, Founder and CEO of DERMALA. “One size just does not fit all when it comes to acne. Most acne treatments have been on the market for decades, but they do not work for everyone. Our proprietary platform combines human microbiome science with data analytics to identify product formulations that deliver the best results and help our customers feel confident, healthy and beautiful in their skin.”
DERMALA launched its #FOBO® (Fear of Breaking Out) Kit, a microbiome-based solution for acne in 2019. It has attracted many loyal customers who value its personalized approach to helping them conquer their “fear of breaking out”. The solution comprises topical acne treatments and oral supplements paired with the DERMALA Acne Tracker app, which customers use to track their skin health.
The Series A financing was co-led by Johnson & Johnson Innovation – JJDC, Inc. and True Wealth Ventures. Seventure Partners, investing via their Health for Life Capital™ Funds, and Cove Fund joined the financing round.
“DERMALA brings together science-based products with robust data analytics to deliver value to the customer with a unique skin health solution,” said Sara T. Brand, Founding General Partner of True Wealth Ventures. “The app enables DERMALA’s product customization and helps customers with treatment compliance. It is truly unique within the OTC consumer dermatology category.”
“Exploring the richness of microbiome biology including prebiotics, probiotics and postbiotics, and combining topical and oral products for OTC dermatology makes great scientific sense,” said Isabelle de Crémoux, CEO and Managing Partner of Seventure Partners. “This, combined with creative marketing and a personalized digital program, positions DERMALA for success after this Series A investment and will allow them to scale up their operations and reach more people in need.”
DERMALA will use the proceeds of the funding round to scale operations, manufacturing, and commercial efforts for its acne products. It will also expand its research and development activities exploring new personalized microbiome-based products for other skin conditions including eczema and skin wellness.
DERMALA, Inc. is a privately-held consumer dermatology company leveraging scientific understanding of the human microbiome to develop novel solutions for acne and other skin conditions. The company’s #FOBO® (Fear of Breaking Out) Kit, a personalized microbiome-based solution for acne, combines patent-pending topical acne treatments with oral supplements and a proprietary DERMALA Acne Tracker app that customers use to track their skin health. For more information, visit dermala.com.